Results 151 to 160 of about 23,790 (200)

Rethinking Neonatal Vaccination Policies: A Neuroimmune Perspective. [PDF]

Iran J Med Sci
Paymani Z, Nazari M, Mirnia K, Sangsari R, Ebrahimi M, Haghighi F.   +5 more
europepmc   +1 more source

Coverage and associated factors of inactivated polio vaccine uptake among children aged 12-23 months in Sub-Saharan Africa. [PDF]

Sci Rep
Wondie WT, Zemariam AB, Gebreegziahber ZA, Legesse BT, Belete KT, Mekonnen GB, Gedefaw GD, Atinafu WT, Seifu BL, Tazeb W.   +9 more
europepmc   +1 more source

Vaccine hesitancy and bone health: Musculoskeletal sequelae of vaccine-preventable diseases. [PDF]

Osteoporos Sarcopenia
Shabbir R, Shabbir Z, Parente PEL, Azad A.   +3 more
europepmc   +1 more source

Evidence of Subclinical Visual Pathway Dysfunction in Polio Survivors: A Visual Evoked Potential Study. [PDF]

Med Princ Pract
Buturak Ş, Fidanci H.
europepmc   +1 more source

The Meningitis and Encephalitis Registry of Lower Saxony, Germany (MERIN) - design and main results of circulating neurotropic pathogen surveillance, 2003 to 2023. [PDF]

Euro Surveill
Wollenweber ML, Beyrer K, Baillot A, Monazahian M, Mertens E, Rettenbacher-Riefler S.   +5 more
europepmc   +1 more source

[Post-polio syndrome].

Revista de saude publica, 2007
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Post-Polio Syndrome☆

La Revue du praticien, 2009
Post-polio syndrome (PPS) is characterized by new muscular weakness, atrophy, general and muscular fatigue, decreased endurance, pain, and loss of function several years after acute polio. Between 20 and 50% of polio survivors are affected. An ongoing, scattered loss of motor neurons, denervation of enlarged motor units, hypertrophic type I muscle ...
François, Genêt, Laurent, Théfenne, François, Boyer   +2 more
  +5 more sources